Skip to main content

Table 4 Differences in treatment, complications, and outcomes in Patients ≥ 80 Years Hospitalized with COVID-19 During the First and Successive Waves

From: Differences in clinical features and mortality in very old unvaccinated patients (≥ 80 years) hospitalized with COVID-19 during the first and successive waves from the multicenter SEMI-COVID-19 Registry (Spain)

 

Total

N (%)

( n  = 5953)

First wave

N (%)

( n  = 4545)

Successive waves

N (%)

( n  = 1408)

p value

Immunomodulatory therapy

 Systemic corticosteroids

2902 (49.0)

1770 (39.2)

1135 (80.6)

 < 0.001

 Tocilizumab

228(3.8)

151 (3.3)

77 (5.5)

 < 0.001

 Colchicine

68 (1.2)

64 (1.4)

4 (0.3)

 < 0.001

 Anakinra

31 (0.5)

21 (0.5)

10 (0.7)

0.270

 Baricitinib

26 (0.5)

21 (0.6)

5 (048)

0.360

Antivirals

 Hydroxychloroquine

3467 (58.5)

3463 (76.5)

4 (0.3)

 < 0.001

 Lopinavir/ritonavir

1893 (31.9)

1885 (41.7)

8 (0.6)

 < 0.001

 Interferon

302 (5.1)

302 (6.7)

0 (0.0)

 < 0.001

 Remdesivir

165 (2.8)

7 (0.2)

158 (11.2)

 < 0.001

 Chloroquine

160 (2.7)

160 (3.5)

0 (0.0)

 < 0.001

 Immunoglobulin

10 (0.2)

10 (0.2)

0 (0.0)

0.131

Antibiotics

 Beta-lactams

4300 (72.6)

3307 (73.2)

993 (70.7)

0.064

 Quinolones

942 (16.0)

689 (15.3)

253 (18.0)

0.017

 Macrolides

3060 (51.7)

2522 (55.9)

538 (33.3)

 < 0.001

Ventilatory therapy

 High-flow nasal cannula oxygen

398(6.7)

312 (6.9)

86 (6.1)

0.288

 Non-invasive mechanical ventilation

249 (4.2)

185 (4.1)

64 (4.6)

0.460

 Invasive mechanic ventilation

70 (1.2)

55 (1.2)

15 (1.1)

0.642

Anticoagulant therapy

 Oral anticoagulants a

428 (7.2)

323 (7.2)

105 (7.5)

0.681

 Low-molecular-weight heparin

425 (83.5)

3678 (81.5)

1247 (88.8)

 < 0.001

Complications

 ARDS, severe

1932 (32.6)

1613 (35.7)

319 (22.7)

 < 0.001

 Acute kidney failure

1370 (23.1)

1059 (23.4)

311 (22.1)

0.324

 Acute heart failure

794 (13.4)

560 (12.4)

234 (16.6)

 < 0.001

 Pneumonia

795 (13.4)

649 (14.3)

146 (10.4)

 < 0.001

 Multiple organ dysfunction syndrome

529 (8.9)

440 (9.7)

89 (6.3)

 < 0.001

 Sepsis

450 (7.6)

366 (8.1)

84 (6.0)

0.009

 Arrhythmia

382 (6.4)

283 (6.3)

99 (7.0)

0.297

 Shock

229 (3.9)

186 (4.1)

43 (3.1)

0.073

 Venous thromboembolism

110 (1.9)

79 (1.7)

43 (3.1)

0.172

 Acute coronary syndrome

84 (1.4)

63 (1.4)

21 (1.2)

0.270

 Stroke

54 (0.9)

43 (0.9)

11 (0.8)

0.562

 Myocarditis

52 (0.9)

37 (0.8)

15 (1.1)

0.381

 Intravascular coagulation

61 (1.0)

52 (1.1)

9 (0.6)

0.098

 Epileptic seizures

44 (0.7)

35 (0.8)

9 (0.6)

0.614

 Acute peripheral ischemic

36 (0.6)

30 (0.7)

6 (0.4)

0.315

Outcomes

 Intensive care unit admission

111 (1.9)

81 (1.8)

30 (1.1)

0.400

 Readmission

341 (5.9)

227 (5.2)

114 (8.1)

 < 0.001

 Death

2697 (41.8)

2004 (44.1)

693 (36.4)

 < 0.001

Days of hospitalization, median (IQR)

14 (10–21)

14 (9–21)

14 (10–21)

0.734

  1. N (%) Number of cases (percentage), ARDS Acute respiratory distress syndrome, IQR Interquartile range:
  2. aAnticoagulant therapy (dicumarin or direct anticoagulant)
  3. Statistically significant differences are indicated in bold